NTRB Stock Overview
Develops a portfolio of transdermal pharmaceutical products. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Nutriband Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.91 |
| 52 Week High | US$9.60 |
| 52 Week Low | US$2.22 |
| Beta | 0.40 |
| 11 Month Change | -22.43% |
| 3 Month Change | -16.07% |
| 1 Year Change | 92.59% |
| 33 Year Change | -9.22% |
| 5 Year Change | -66.30% |
| Change since IPO | -13.21% |
Recent News & Updates
Recent updates
Is Nutriband (NASDAQ:NTRB) A Risky Investment?
Mar 31
Is Nutriband (NASDAQ:NTRB) Weighed On By Its Debt Load?
Sep 13Nutriband GAAP EPS of -$0.12, revenue of $0.5M
Sep 08Nutriband opens a new branch in Ecuador with plans to expand into the South American market
Jul 22Nutriband: Advancing Transdermal Delivery Of Injectable Drugs
Nov 01Does Nutriband (NASDAQ:NTRB) Have A Healthy Balance Sheet?
Oct 06Shareholder Returns
| NTRB | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 2.1% | -5.3% | -1.2% |
| 1Y | 92.6% | 8.7% | 30.4% |
Return vs Industry: NTRB exceeded the US Pharmaceuticals industry which returned 8.7% over the past year.
Return vs Market: NTRB exceeded the US Market which returned 30.4% over the past year.
Price Volatility
| NTRB volatility | |
|---|---|
| NTRB Average Weekly Movement | 15.7% |
| Pharmaceuticals Industry Average Movement | 9.4% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: NTRB's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: NTRB's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | n/a | Gareth Sheridan | www.nutriband.com |
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company’s lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops AVERSA buprenorphine and AVERSA methylphenidate, and other transdermal pharmaceutical products.
Nutriband Inc. Fundamentals Summary
| NTRB fundamental statistics | |
|---|---|
| Market cap | US$54.48m |
| Earnings (TTM) | -US$7.24m |
| Revenue (TTM) | US$1.80m |
30.2x
P/S Ratio-7.5x
P/E RatioIs NTRB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NTRB income statement (TTM) | |
|---|---|
| Revenue | US$1.80m |
| Cost of Revenue | US$1.20m |
| Gross Profit | US$606.49k |
| Other Expenses | US$7.85m |
| Earnings | -US$7.24m |
Last Reported Earnings
Jul 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.65 |
| Gross Margin | 33.62% |
| Net Profit Margin | -401.62% |
| Debt/Equity Ratio | 1.6% |
How did NTRB perform over the long term?
See historical performance and comparison